Related Experiment Videos
Cytotoxic chemotherapeutic agents under development with a possible future role in prostate cancer
The Prostate
|January 1, 1984
Abstract:
New cytotoxic chemotherapeutic compounds under development or in early clinical trial which might be considered for clinical evaluation in prostatic carcinoma are discussed. The following classes of agents are considered: lipid-soluble antifolates, anthracyclines, nitrosoureas, and platinum analogues. A group of miscellaneous compounds is also discussed.
Insights
New chemotherapy drugs for prostate cancer are being evaluated. This includes lipid-soluble antifolates, anthracyclines, nitrosoureas, platinum analogues, and other agents for potential clinical use.
Area of Science:
- Oncology
- Pharmacology
Background:
- Prostatic carcinoma remains a significant health concern.
- Development of novel chemotherapeutic agents is crucial for improving treatment outcomes.
Purpose of the Study:
- To review emerging cytotoxic chemotherapeutic compounds for potential clinical evaluation in prostate cancer.
- To categorize these agents into distinct therapeutic classes.
Main Methods:
- Literature review of compounds in development or early clinical trials.
- Classification of agents based on their chemical structure and mechanism of action.
Main Results:
- Identified several classes of promising cytotoxic agents.
- Included lipid-soluble antifolates, anthracyclines, nitrosoureas, and platinum analogues.
- Also considered a miscellaneous group of compounds.
Conclusions:
- Several new classes of chemotherapeutic agents show potential for prostate cancer treatment.
- Further clinical evaluation is warranted for these novel compounds.